Ask the Expert

Advances in Pulmonary Hypertension

¹ 

关键词: Cardiology;    Pulmonology;    Pharmacy;    WHO Group 1- Pulmonary Arterial Hypertension;    PH Medications;    Oral therapy;    Inhaled therapy;    Phosphodiesterase Inhibitors (PDE-5 Inhibitors);    Prostacyclin;    Endothelin Receptor Antagonists;    nitric oxide;    endothelial dysfunction;    pre-clinical research;    CME;    CEU;    Medicare;    Classification;   

DOI  :  

学科分类：医学（综合）

来源: Pulmonary Hypertension Association

【 摘 要 】

Kshettry and colleagues retrospectively analyzed 107 lung allograft recipients for the development of bronchiolitis obliterans to evaluate PAH as a potential risk factor. They demonstrated that patients with PAH developed bronchiolitis obliterans more often (39% vs 19%; P=0.044) and more rapidly (12 months vs 15 months; P=0.05) than those with other diagnoses.57 However, results from other investigators have not corroborated these findings. Sundaresan at Washington University reported no significant tendency for development of bronchiolitis obliterans syndrome (surrogate for bronchiolitis obliterans) in patients with PAH.58,59 At present there is no consensus as to whether PAH is a risk factor for the development of bronchiolitis obliterans.

【 授权许可】

All Rights reserved